This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laohavaleeson, S.
Right arrow Articles by Nicolau, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laohavaleeson, S.
Right arrow Articles by Nicolau, D. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2008, p. 2389-2394, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.01422-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus Strains{triangledown}

Somvadee Laohavaleeson, Pamela R. Tessier, and David P. Nicolau*

Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102

Received 2 November 2007/ Returned for modification 14 January 2008/ Accepted 5 April 2008

Ceftobiprole (BPR) is an investigational cephalosporin with activity against Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) strains. The pharmacodynamic (PD) profile of BPR against S. aureus strains with a variety of susceptibility phenotypes in an immunocompromised murine pneumonia model was characterized. The BPR MICs of the test isolates ranged from 0.25 to 2 µg/ml. Pharmacokinetic (PK) studies were conducted with infected neutropenic BALB/c mice; and the BPR concentrations were measured in plasma, epithelial lining fluid (ELF), and lung tissue. PD studies with these mice were undertaken with eight S. aureus isolates (two methicillin-susceptible S. aureus strains, three hospital-acquired MRSA strains, and three community-acquired MRSA strains). Subcutaneous BPR doses of 2 to 125 mg/kg of body weight/day were administered, and the change in the number of log10 CFU/ml in lungs was evaluated after 24 h of therapy. The PD profile was characterized by using the free drug exposures (f) determined from the following parameters: the percentage of time that the concentration was greater than the MIC (T > MIC), the maximum concentration in serum/MIC, and the area under the concentration-time curve/MIC. The BPR PK parameters were linear over the dose range studied in plasma, and the ELF concentrations ranged from 60 to 94% of the free plasma concentration. fT > MIC was the parameter that best correlated with efficacy against a diverse array of S. aureus isolates in this murine pneumonia model. The 80% effective dose (ED80), ED50, and stasis exposures appeared to be similar among the isolates studied. BPR exerted maximal antibacterial effects when fT > MIC ranged from 6 to 22%, regardless of the phenotypic profile of resistance to β-lactam, fluoroquinolone, erythromycin, clindamycin, or tetracycline antibiotics.

* Corresponding author. Mailing address: Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102. Phone: (860) 545-3941. Fax: (860) 545-3992. E-mail: dnicola{at}harthosp.org

{triangledown} Published ahead of print on 14 April 2008.

Antimicrobial Agents and Chemotherapy, July 2008, p. 2389-2394, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.01422-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Crandon, J. L., Kim, A., Nicolau, D. P. (2009). Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J Antimicrob Chemother 64: 837-839 [Abstract] [Full Text]  
  • Zhanel, G. G., Voth, D., Nichol, K., Karlowsky, J. A., Noreddin, A. M., Hoban, D. J. (2009). Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 64: 364-369 [Abstract] [Full Text]  
  • Louie, A., Fregeau, C., Liu, W., Kulawy, R., Drusano, G. L. (2009). Pharmacodynamics of Levofloxacin in a Murine Pneumonia Model of Pseudomonas aeruginosa Infection: Determination of Epithelial Lining Fluid Targets. Antimicrob. Agents Chemother. 53: 3325-3330 [Abstract] [Full Text]  
  • Rodvold, K. A., Nicolau, D. P., Lodise, T. P., Khashab, M., Noel, G. J., Kahn, J. B., Gotfried, M., Murray, S. A., Nicholson, S., Laohavaleeson, S., Tessier, P. R., Drusano, G. L. (2009). Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole. Antimicrob. Agents Chemother. 53: 3294-3301 [Abstract] [Full Text]  
  • Crandon, J. L., Banevicius, M. A., Nicolau, D. P. (2009). Pharmacodynamics of Tigecycline against Phenotypically Diverse Staphylococcus aureus Isolates in a Murine Thigh Model. Antimicrob. Agents Chemother. 53: 1165-1169 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»